Heart drug hopes to shield dialysis patients from deadly attacks

NCT ID NCT01475123

Ongoing Disease control Sponsor: Kumamoto University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether the drug nicorandil can lower the risk of serious heart problems like heart attacks and strokes in people with coronary artery disease who are on kidney dialysis. Researchers are giving 15 mg of nicorandil daily to 268 participants and tracking heart-related events over time. The goal is to see if this drug offers extra protection for this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nicorandil
What this could lead to: If it works, this could point toward a way to prevent heart attacks and strokes in people with kidney disease who are on dialysis.
What could go wrong: This is a relatively small, single-country trial, so results may not apply to everyone. Nicorandil may not reduce heart events as hoped, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease coronary artery disorder end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE END-STAGE RENAL DISEASE

Contacts and locations

Locations

Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University

Kumamoto, 860-8556, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.